Bladder control problems affect an estimated 43 million – or one in six – U.S. adults. Of those, nearly 16 million people have urge urinary incontinence, a common symptom of overactive bladder (OAB) ...
The Implantable Tibial Neuromodulation (ITNM) device will expand treatment options for the 16 million people living with urinary urges and involuntary leaks GALWAY, Ireland, Sept. 19, 2025 /PRNewswire ...
The US Food and Drug Administration (FDA) has approved Medtronic’s Altaviva device, intended for the treatment of urge urinary incontinence. This implantable tibial neuromodulation (ITNM) device ...
Medtronic plc MDT recently received Food and Drug Administration (“FDA”) approval for the minimally invasive implantable tibial neuromodulation (ITNM) Altaviva device. The therapy is inserted near the ...
Medtronic said it has won an FDA nod for an implantable tibial neuromodulation therapy that treats urge urinary incontinence. The Altaviva device is inserted near the ankle. The Dublin-based company ...
As US medtech heavyweights pour billions into bladder-control therapies for ageing populations, an Australian company is ...
Medtronic is upping the ante in a patent dispute with competitor Axonics Inc. that has already lasted more than four years. The dispute centers on Medtronic’s InterStim device, an implanted ...
Dr. Keith Roach, M.D. DEAR DR. ROACH: My daughter, who is 50, recently went to a urologist for bladder retention issues. She had several tests performed. My daughter’s doctor told her that the ...
The Implantable Tibial Neuromodulation (ITNM) device will expand treatment options for the 16 million people living with urinary urges and involuntary leaks Bladder control problems affect an ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results